A citation-based method for searching scientific literature

Harold E Bays, Plamen Kozlovski, Qing Shao, Pieter Proot, Deborah Keefe. Obesity (Silver Spring) 2020
Times Cited: 5







List of co-cited articles
21 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


The effects of licogliflozin, a dual SGLT1/2 inhibitor, on body weight in obese patients with or without diabetes.
Yan-Ling He, William Haynes, Charles D Meyers, Ahmed Amer, Yiming Zhang, Ping Mahling, Anisha E Mendonza, Shenglin Ma, William Chutkow, Eric Bachman. Diabetes Obes Metab 2019
26
80

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Juan Pablo Frias, Michael A Nauck, Joanna Van, Mark E Kutner, Xuewei Cui, Charles Benson, Shweta Urva, Ruth E Gimeno, Zvonko Milicevic, Deborah Robins,[...]. Lancet 2018
182
60

MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.
Philip Ambery, Victoria E Parker, Michael Stumvoll, Maximilian G Posch, Tim Heise, Leona Plum-Moerschel, Lan-Feng Tsai, Darren Robertson, Meena Jain, Marcella Petrone,[...]. Lancet 2018
88
60

Development of SGLT1 and SGLT2 inhibitors.
Timo Rieg, Volker Vallon. Diabetologia 2018
63
40

A novel dual amylin and calcitonin receptor agonist, KBP-089, induces weight loss through a reduction in fat, but not lean mass, while improving food preference.
Sofie Gydesen, Sara Toftegaard Hjuler, Zenia Freving, Kim Vietz Andreassen, Nina Sonne, Lars I Hellgren, Morten Asser Karsdal, Kim Henriksen. Br J Pharmacol 2017
24
40

Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
Vlad Ratziu, Stephen A Harrison, Sven Francque, Pierre Bedossa, Philippe Lehert, Lawrence Serfaty, Manuel Romero-Gomez, Jérôme Boursier, Manal Abdelmalek, Steve Caldwell,[...]. Gastroenterology 2016
462
40

The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial.
Rohit Loomba, Eric Lawitz, Parvez S Mantry, Saumya Jayakumar, Stephen H Caldwell, Hays Arnold, Anna Mae Diehl, C Stephen Djedjos, Ling Han, Robert P Myers,[...]. Hepatology 2018
231
40

Dose-dependent reduction in body weight with LIK066 (licogliflozin) treatment in Japanese patients with obesity.
Koutaro Yokote, Misako Sano, Isao Tsumiyama, Deborah Keefe. Diabetes Obes Metab 2020
4
50

Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Frank L Greenway, Ken Fujioka, Raymond A Plodkowski, Sunder Mudaliar, Maria Guttadauria, Janelle Erickson, Dennis D Kim, Eduardo Dunayevich. Lancet 2010
391
40

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
Xavier Pi-Sunyer, Arne Astrup, Ken Fujioka, Frank Greenway, Alfredo Halpern, Michel Krempf, David C W Lau, Carel W le Roux, Rafael Violante Ortiz, Christine Bjørn Jensen,[...]. N Engl J Med 2015
608
40

Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes.
Priscilla Hollander, Alok K Gupta, Raymond Plodkowski, Frank Greenway, Harold Bays, Colleen Burns, Preston Klassen, Ken Fujioka. Diabetes Care 2013
177
40

A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II).
Caroline M Apovian, Louis Aronne, Domenica Rubino, Christopher Still, Holly Wyatt, Colleen Burns, Dennis Kim, Eduardo Dunayevich. Obesity (Silver Spring) 2013
225
40


Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.
W Timothy Garvey, Donna H Ryan, Michelle Look, Kishore M Gadde, David B Allison, Craig A Peterson, Michael Schwiers, Wesley W Day, Charles H Bowden. Am J Clin Nutr 2012
296
40

Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP).
David B Allison, Kishore M Gadde, William Timothy Garvey, Craig A Peterson, Michael L Schwiers, Thomas Najarian, Peter Y Tam, Barbara Troupin, Wesley W Day. Obesity (Silver Spring) 2012
279
40

Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
Melanie J Davies, Richard Bergenstal, Bruce Bode, Robert F Kushner, Andrew Lewin, Trine Vang Skjøth, Arne Haahr Andreasen, Christine Bjørn Jensen, Ralph A DeFronzo. JAMA 2015
306
40


Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
40

Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial.
Thomas A Wadden, John P Foreyt, Gary D Foster, James O Hill, Samuel Klein, Patrick M O'Neil, Michael G Perri, F Xavier Pi-Sunyer, Cheryl L Rock, Janelle S Erickson,[...]. Obesity (Silver Spring) 2011
237
40



Dorzagliatin (HMS5552), a novel dual-acting glucokinase activator, improves glycaemic control and pancreatic β-cell function in patients with type 2 diabetes: A 28-day treatment study using biomarker-guided patient selection.
Xiao-Xue Zhu, Da-Long Zhu, Xiao-Ying Li, Ya-Lin Li, Xiao-Wei Jin, Tian-Xin Hu, Yu Zhao, Yong-Guo Li, Gui-Yu Zhao, Shuang Ren,[...]. Diabetes Obes Metab 2018
10
20

Effects of MetAP2 inhibition on hyperphagia and body weight in Prader-Willi syndrome: A randomized, double-blind, placebo-controlled trial.
Shawn E McCandless, Jack A Yanovski, Jennifer Miller, Cary Fu, Lynne M Bird, Parisa Salehi, Christine L Chan, Diane Stafford, M Jennifer Abuzzahab, David Viskochil,[...]. Diabetes Obes Metab 2017
39
20

Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis.
Jay S Skyler, George L Bakris, Ezio Bonifacio, Tamara Darsow, Robert H Eckel, Leif Groop, Per-Henrik Groop, Yehuda Handelsman, Richard A Insel, Chantal Mathieu,[...]. Diabetes 2017
161
20

Sotagliflozin: First Global Approval.
Anthony Markham, Susan J Keam. Drugs 2019
12
20

Fibroblast Growth Factor 21-Metabolic Role in Mice and Men.
Harald Staiger, Michaela Keuper, Lucia Berti, Martin Hrabe de Angelis, Hans-Ulrich Häring. Endocr Rev 2017
88
20

The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy.
Pascale Fouqueray, Valdis Pirags, Silvio E Inzucchi, Clifford J Bailey, Guntram Schernthaner, Michaela Diamant, Harold E Lebovitz. Diabetes Care 2013
32
20


EGT1442, a potent and selective SGLT2 inhibitor, attenuates blood glucose and HbA(1c) levels in db/db mice and prolongs the survival of stroke-prone rats.
Wenbin Zhang, Ajith Welihinda, Jordan Mechanic, Haifeng Ding, Liangcheng Zhu, Yuan Lu, Zhongping Deng, Zelin Sheng, Binhua Lv, Yuanwei Chen,[...]. Pharmacol Res 2011
29
20

G Protein-Coupled Receptor 119 (GPR119) Agonists for the Treatment of Diabetes: Recent Progress and Prevailing Challenges.
Kurt Ritter, Christian Buning, Nis Halland, Christoph Pöverlein, Lothar Schwink. J Med Chem 2016
62
20

GLP-1 receptor agonists: differentiation within the class.
Simeon I Taylor. Lancet Diabetes Endocrinol 2018
19
20

2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
John B Buse, Deborah J Wexler, Apostolos Tsapas, Peter Rossing, Geltrude Mingrone, Chantal Mathieu, David A D'Alessio, Melanie J Davies. Diabetes Care 2020
216
20

Efficacy and safety of methionine aminopeptidase 2 inhibition in type 2 diabetes: a randomised, placebo-controlled clinical trial.
Joseph Proietto, Jaret Malloy, Dongliang Zhuang, Mark Arya, Neale D Cohen, Ferdinandus J de Looze, Christopher Gilfillan, Paul Griffin, Stephen Hall, Thomas Nathow,[...]. Diabetologia 2018
8
20


Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.
M Angelyn Bethel, Rishi A Patel, Peter Merrill, Yuliya Lokhnygina, John B Buse, Robert J Mentz, Neha J Pagidipati, Juliana C Chan, Stephanie M Gustavson, Nayyar Iqbal,[...]. Lancet Diabetes Endocrinol 2018
242
20

The Dual Amylin and Calcitonin Receptor Agonist KBP-088 Induces Weight Loss and Improves Insulin Sensitivity Superior to Chronic Amylin Therapy.
Anna Thorsø Larsen, Nina Sonne, Kim Vietz Andreassen, Kristoffer Gehring, Morten Asser Karsdal, Kim Henriksen. J Pharmacol Exp Ther 2019
7
20

NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Stephen A Harrison, Mary E Rinella, Manal F Abdelmalek, James F Trotter, Angelo H Paredes, Hays L Arnold, Marcelo Kugelmas, Mustafa R Bashir, Mark J Jaros, Lei Ling,[...]. Lancet 2018
172
20

Pharmacokinetics and Pharmacodynamics of Henagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, in Chinese Patients with Type 2 Diabetes Mellitus.
Xiaolan Yong, Aidong Wen, Xiangyang Liu, Haiyan Liu, Yan-Ping Liu, Nan Li, Tingting Hu, Ying Chen, Minquan Wang, Lantian Wang,[...]. Clin Drug Investig 2016
5
20

Glutazumab, a novel long-lasting GLP-1/anti-GLP-1R antibody fusion protein, exerts anti-diabetic effects through targeting dual receptor binding sites.
Caina Li, Miaomiao Yang, Xiaofeng Wang, Hua Zhang, Chenjiang Yao, Sujuan Sun, Quan Liu, Hao Pan, Shuainan Liu, Yi Huan,[...]. Biochem Pharmacol 2018
10
20

Uniting GDF15 and GFRAL: Therapeutic Opportunities in Obesity and Beyond.
Shannon E Mullican, Shamina M Rangwala. Trends Endocrinol Metab 2018
42
20

Non-alcoholic fatty liver disease and diabetes.
Jonathan M Hazlehurst, Conor Woods, Thomas Marjot, Jeremy F Cobbold, Jeremy W Tomlinson. Metabolism 2016
174
20


Oral semaglutide for the treatment of type 2 diabetes.
Maka S Hedrington, Stephen N Davis. Expert Opin Pharmacother 2019
15
20

Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide.
Julio Rosenstock, Christopher H Sorli, Michael E Trautmann, Cristóbal Morales, Ulrich Wendisch, George Dailey, Marcus Hompesch, In Young Choi, Jahoon Kang, John Stewart,[...]. Diabetes Care 2019
5
20

The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes.
Gregory Gaich, Jenny Y Chien, Haoda Fu, Leonard C Glass, Mark A Deeg, William L Holland, Alexei Kharitonenkov, Thomas Bumol, Holger K Schilske, David E Moller. Cell Metab 2013
493
20




Investigational glucagon receptor antagonists in Phase I and II clinical trials for diabetes.
André J Scheen, Nicolas Paquot, Pierre J Lefèbvre. Expert Opin Investig Drugs 2017
31
20



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.